Prognostic value of serum carbohydrate 19-9 in patients receiving gemcitabine-based neoadjuvant therapy for pancreatic cancer

Authors :: Stuart R. Gordon
Spencer L. James
Kathryn Cunningham Hourdequin
Kerrington D. Smith
Bassem I. Zaki
Richard J. Barth
Joseph J. Shatzel
J. Marc Pipas
Michael J. Tsapakos
Timothy B. Gardner
Kabir Mody
John E. Sutton
Elizabeth Boutin McGrath
Thomas A. Colacchio
Arief A. Suriawinata
Rebecca Wang
Gregory H. Ripple
Gregory J. Tsongalis
Source :: Journal of Clinical Oncology. 32:e15189-e15189
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: e15189 Background: The role of neoadjuvant therapy in pancreatic ductal adenocarcinoma (PDAC) remains unclear, but has demonstrated benefit in many studies. CA 19-9 is a commonly used tumor marker ...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Pancreatic ductal adenocarcinoma
endocrine system diseases
business.industry
medicine.medical_treatment
medicine.disease
digestive system diseases
Gemcitabine
Pancreatic cancer
Internal medicine
medicine
In patient
business
Neoadjuvant therapy
medicine.drug
Tumor marker

Tools